DCVC Bio managing partners Kiersten Stead and John Hamer
September 30, 2024 10:22 AM EDT
Financing
Startups

DCVC Bio reels in $400M third fund

Kyle LaHucik

Senior Reporter

DCVC Bio con­firmed it has put to­geth­er a $400 mil­lion third fund, four years af­ter rais­ing $350 mil­lion in its sopho­more ef­fort …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times